---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-008941"
form_type: "8-K"
ticker: "NSPR"
cik: "0001433607"
company_name: "InspireMD, Inc."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:33:03.893949+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# InspireMD Q4 revenue jumps 71.6% to $1.76M; net loss $0.16 per share

## Summary
- Record Q4 CGuard EPS revenue of $1.76M, up 71.6% YoY; 3,107 stents sold (+74.5%).
- C-GUARDIANS trial showed 0.95% DSMI rate at 30 days; PMA submission expected mid-2024.
- CE Mark recertified under EU MDR, enabling new product development pathway.
- CMS expanded CAS coverage to asymptomatic and standard-risk patients, widening U.S. market.
- Cash and equivalents $39.0M at Dec 31, 2023, up from $17.8M a year earlier.

## SEC filing metadata
- accession: 0001493152-24-008941
- form_type: 8-K
- ticker: NSPR
- cik: 0001433607
- company_name: InspireMD, Inc.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1433607/000149315224008941/0001493152-24-008941-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1433607/000149315224008941/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-008941
- JSON: https://secwatch.observer/filing/0001493152-24-008941.json
- Plain text: https://secwatch.observer/filing/0001493152-24-008941.txt

## Key facts
- Earnings Releases
  InspireMD, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $1,761,000.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: $1,761,000
  - Result: reported results
  source text: For the fourth quarter of 2023, total revenue increased 71.6%, to $1,761,000, from $1,026,000 during the fourth quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1433607/000149315224008941/0001493152-24-008941-index.htm
- Earnings Releases
  InspireMD, Inc. reported financial results for the full-year ended December 31, 2023.
  - Period: the full-year ended December 31, 2023
  - Result: reported results
  source text: InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuardTM Embolic Prevention System (EPS) for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced financial and operating results for the fourth quarter and full-year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1433607/000149315224008941/0001493152-24-008941-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.